Merck Adds To Diabetes Franchise With SmartCells Acquisition
This article was originally published in The Pink Sheet Daily
Executive SummaryMerck announced Dec.2 that it is acquiring privately-held SmartCells for the company's preclinical SmartInsulin diabetes program in a deal potentially worth as much as $500 million. The acquisition will help bolster sales of Merck's blockbuster diabetes drug Januvia.
Register for our free email digests: